- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Suzette Kox, MPharm: Global Reference Products in Biosimilar Development
Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses progress made toward the use of global reference products in biosimilar development.
Transcript
I’m quite optimistic on that. Why I’m optimistic is because the [World Health Organization, WHO] at the moment works on the pilot prequalification process for trastuzumab and for rituximab.
What does it mean in practice? If, for example, a trastuzumab is approved, is prequalified by the WHO, that could be, for example, a US-approved product or a biosimilar, or a European biosimilar, they have used a comparator in biosimilar development, but the product itself will be used around the world where it has been part of [United Nations, UN] tender or governments want to have access to that prequalified product. Automatically, that comparator, which has been used in the biosimilar development, becomes a global comparator product.
I think we will take that up with the WHO once that process is completed so that we get a list of comparator products which can be used for biosimilar development. They have defined that already in their procedure itself, so I think that’s very promising, because we are really here in the practice, and we can build on that.
Furthermore, we have identified that a number of countries around the world accept, already, a foreign comparator product in biosimilar development which is representative of their reference product. As IGBA, we are for the moment working on a positive list of those countries, and we will make that public once that task is completed. So I’m quite positive on those developments.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
